Table 1 Clinical and tumor characteristics, therapeutic regimens, and clinical response in 355 cervical cancer patients
Characteristics | Number (%) |
|---|---|
Histopathology | Â |
 Squamous cell carcinoma | 209 (58.8) |
 Adenocarcinoma | 120 (34.0) |
 Adenosquamous carcinoma | 15 (4.1) |
 Serous carcinoma | 1 (0.3) |
 Clear cell carcinoma | 3 (0.8) |
 Mixed types | 1 (0.3) |
 Undifferentiated carcinoma | 5 (1.4) |
 Adenosarcoma | 1 (0.3) |
Initial FIGO stage | Â |
 IA | 6 (1.7) |
 IB | 53 (14.9) |
 IIA | 15 (4.2) |
 IIB | 90 (25.4) |
 IIIA | 1 (0.3) |
 IIIB | 127 (35.8) |
 IVA | 9 (2.5) |
 IVB | 50 (14.1) |
 Inadvertent hysterectomy | 3 (0.8) |
 No data | 1 (0.3) |
Primary treatment | Â |
 Radiotherapy | 42 (11.8) |
 Concurrent chemoradiotherapy | 209 (58.9) |
 Surgery | 42 (11.8) |
 Chemotherapy | 62 (17.5) |
Disease sites before chemotherapy initiation | Â |
 Locoregional | 138 (38.9) |
 Distant | 90 (25.4) |
 Both | 127 (35.8) |
Chemotherapeutic agents | Â |
 Platinumsa + Paclitaxel | 255 (71.8) |
 Platinumsa + Fluorouracil based | 27 (7.6) |
 Cisplatin + Topotecan | 10 (2.8) |
 Cisplatin + Mitomycin | 13 (3.7) |
 Cisplatin + Ifosfamide | 12 (3.4) |
 Cisplatin + Gemcitabine | 1 (0.3) |
 Single drugsb | 37 (10.4) |
Response to treatment | Â |
 Complete response | 79 (22.3) |
 Partial response | 54 (15.2) |
 Stable of disease | 108 (30.4) |
 Disease progression | 114 (32.1) |
Recurrent or persistent disease | Â |
 No recurrence | 35 (9.9) |
 Recurrence after complete response | 44 (12.4) |
 Persistent disease | 276 (77.7) |
Last contact outcomes | Â |
 Alive without disease | 39 (11.0) |
 Alive with disease | 204 (57.5) |
 Death without disease | 0 |
 Death with disease | 112 (31.5) |